By Marie Rosenthal, MS
The CDC’s Advisory Committee on Immunization Practices voted to recommend the virus-like particle-based chikungunya vaccine, recombinant (CHIK-VLP; Vimkunya, Bavarian Nordic) for certain populations. However, the CDC has not acted yet on this or other recommendations the ACIP made April 16.
The CHIK-VLP vaccine, an adjuvanted VLP-based vaccine, is indicated for people 12 years of age and older traveling to a country or territory where there is a chikungunya